Gamida Cell (GMDA) Rallies On Announcing First Dose of Phase 1/2 Study
Gamida Cell (GMDA) soared 28% upon announcing the news that they dosed the first patient in their Phase 1/2 study of NK Cell Therapy Candidate GDA-201.
GMDA is the leader in developing NAM-enabled cell therapy candidates for patients with hematologic and solid cancers.
“We are excited to further advance the development of GDA-201, a NAM-enabled natural killer (NK) cell therapy candidate which we believe has the potential to be a new readily available, cryopreserved treatment option for cancer patients with relapsed/refractory lymphoma,” said Ronit Simantov, M.D., chief medical and scientific officer of Gamida Cell. “Our NK cells elicited an adaptive immune response in patients in the previous investigator-sponsored study with the fresh formulation of GDA-201, potentially leading to durable remissions. We are truly grateful for the contribution of all the participants and clinical collaborators who will allow us to continue studying GDA-201 in this multi-center open label trial.”
GMDA is housed in the PRISM Vaccines & Cell Therapy Index, which is up 0.8% for the day, led by GMDA’s performance.
About NAM Technology
Our NAM-enabled technology, supported by positive Phase 3 data for omidubicel, is designed to enhance the number and functionality of targeted cells, enabling us to pursue a curative approach that moves beyond what is possible with existing therapies. Leveraging the unique properties of NAM, we can expand and metabolically modulate multiple cell types — including stem cells and NK cells — with appropriate growth factors to maintain the cells’ active phenotype and enhance potency. Additionally, our NAM technology improves the metabolic fitness of cells, allowing for continued activity throughout the expansion process.